GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

LV-305 is under clinical development by Merck and currently in Phase I for Synovial Sarcoma. According to GlobalData, Phase I drugs for Synovial Sarcoma have a 76% phase transition success rate (PTSR) ...

Liposarcoma (LPS) is the most common soft tissue sarcoma (STS) in adults ... lipomatous tumor (ATL)/well-differentiated LPS (WDLPS), dedifferentiated LPS (DDLPS), myxoid LPS (MLPS), pleomorphic LPS ...

The wound was disinfected and dressed with a bandage, but months later and the surgeon noticed something was seriously wrong ...

Recent advancements in medical technology have revolutionized limb-salvage surgery and functional reconstruction for pediatric bone and soft tissue tumors.

Adaptimmune has more good news from its SPEAR T-cell therapy, yesterday unveiling encouraging early results in four patients with myxoid/round ... a rare sarcoma. The trial reported three partial ...

Share on Pinterest Dietary fructose may contribute to cancer tumor growth ... I see this often in crackers, cookies, soft drinks, and juices,” she told us. “Keep in mind, there is no reason ...

Scientists made the discovery after examining 81 cancerous colon tumours and their surrounding tissue. The tumours contained a high number of lipids, microscopic fatty compounds produced when ...

New research by a team of Indiana University School of Medicine scientists and their collaborators has uncovered a novel vulnerability in prostate cancer animal models that starves prostate tumors ...

The problem with all tumours of the brain is that we cannot remove them totally, if they are within the brain tissue itself. There will be some residue left behind, and this is because we cannot ...

Dr Sharma told us: "Dense breast tissue appears white on mammograms, which can mask potential tumours (also white), therefore reducing mammogram effectiveness. "It’s important to note that ...

Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor, to assess its safety ...